Active ingredient description

Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarisation. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intra-cellular calcium concentrations facilitates exocytosis of acetylcholine-containing vesicles, which in turn enhances neuromuscular transmission.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Structured Product Labeling (SPL/PLR)
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₅H₇N₃
Molecular mass: 109.132 g/mol

External identifiers

CAS Substance: 54-96-6
DrugBank Drug: DB11640
PubChem Compound: 5918
RxNorm Ingredient: 2106338
SNOMED-CT Concept: 782973004
Amifampridine (substance)
UNII Identifier: RU4S6E2G0J


Amifampridine is an active ingredient of these brands:

United States (US)

Austria (AT)

Canada (CA)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.